American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of June 30, 2018, it owned and operated 233 dialysis clinics in partnership with 400 nephrologist partners treating approximately 16,000 patients in 26 states and the District of Columbia.
Read More…
Industry, Sector and Symbol
Industry Miscellaneous health & allied services, not elsewhere classified
Sub-IndustryN/A
SectorMedical
Phone978-922-3080
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$805.78 million
Profitability
Miscellaneous
Employees4,692
Next Earnings Date9/17/2019 (Estimated)
OptionableOptionable
American Renal Associates (NYSE:ARA) Frequently Asked Questions
What is American Renal Associates' stock symbol?
American Renal Associates trades on the New York Stock Exchange (NYSE) under the ticker symbol "ARA."
How were American Renal Associates' earnings last quarter?
American Renal Associates Holdings Inc (NYSE:ARA) issued its quarterly earnings results on Tuesday, August, 7th. The company reported $0.20 EPS for the quarter, topping the Zacks' consensus estimate of $0.17 by $0.03. The company had revenue of $217.18 million for the quarter, compared to analysts' expectations of $203.70 million. American Renal Associates had a positive return on equity of 12.33% and a negative net margin of 2.50%. View American Renal Associates' Earnings History.
When is American Renal Associates' next earnings date?
What price target have analysts set for ARA?
7 equities research analysts have issued twelve-month price targets for American Renal Associates' shares. Their predictions range from $7.00 to $24.00. On average, they expect American Renal Associates' stock price to reach $13.75 in the next year. This suggests a possible upside of 40.2% from the stock's current price. View Analyst Price Targets for American Renal Associates.
What is the consensus analysts' recommendation for American Renal Associates?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for American Renal Associates in the last year. There are currently 6 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for American Renal Associates.
Has American Renal Associates been receiving favorable news coverage?
Media coverage about ARA stock has been trending somewhat positive this week, according to InfoTrie. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. American Renal Associates earned a daily sentiment score of 0.9 on InfoTrie's scale. They also gave headlines about the company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for American Renal Associates.
Who are some of American Renal Associates' key competitors?
What other stocks do shareholders of American Renal Associates own?
Who are American Renal Associates' key executives?
American Renal Associates' management team includes the folowing people:
- Mr. Joseph A. Carlucci, Co-Founder, CEO & Chairman (Age 65)
- Mr. Syed T. Kamal, Founder, Pres & Director (Age 66)
- Mr. Mark C. Herbers, Interim CFO & Interim Chief Accounting Officer (Age 64)
- Dr. Don E. Williamson, Exec. VP & COO (Age 56)
- Mr. Richard Pacheco CFE, AVA, MBA, VP of Admin.
When did American Renal Associates IPO?
(ARA) raised $161 million in an IPO on Thursday, April 21st 2016. The company issued 7,500,000 shares at $20.00-$23.00 per share. BofA Merrill Lynch, Barclays and Goldman Sachs acted as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey and Leerink Partners were co-managers.
Who are American Renal Associates' major shareholders?
American Renal Associates' stock is owned by many different of retail and institutional investors. Top institutional investors include Van Berkom & Associates Inc. (8.17%), BlackRock Inc. (3.68%), Vanguard Group Inc. (2.76%), JPMorgan Chase & Co. (2.35%), Renaissance Technologies LLC (1.96%) and Northern Trust Corp (0.54%). View Institutional Ownership Trends for American Renal Associates.
Which major investors are selling American Renal Associates stock?
Which major investors are buying American Renal Associates stock?
ARA stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, JPMorgan Chase & Co., Marshall Wace LLP, DekaBank Deutsche Girozentrale, Cubist Systematic Strategies LLC, Charles Schwab Investment Management Inc. and A.R.T. Advisors LLC. View Insider Buying and Selling for American Renal Associates.
How do I buy shares of American Renal Associates?
Shares of ARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is American Renal Associates' stock price today?
One share of ARA stock can currently be purchased for approximately $9.81.
How big of a company is American Renal Associates?
What is American Renal Associates' official website?
How can I contact American Renal Associates?
American Renal Associates' mailing address is 500 CUMMINGS CENTER SUITE 6550, BEVERLY MA, 01915. The company can be reached via phone at 978-922-3080 or via email at [email protected]
MarketBeat Community Rating for American Renal Associates (NYSE ARA)
MarketBeat's community ratings are surveys of what our community members think about American Renal Associates and other stocks. Vote "Outperform" if you believe ARA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARA will underperform the S&P 500 over the long term. You may vote once every thirty days.
